- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Ascent Pediatrics expands
Ascent Pediatrics announced that it plans to expand its field sales force.
One year after Ascent Pediatrics was formed to develop and promote pharmaceutical products exclusively to children, the Wilmington, DE-based firm announced that it plans to expand its field sales force.
In response to a recently announced agreement with Warner-Lambert Co., Ascent will expand its sales force by 34% in order to copromote the cephalosporin antibiotic Omnicef® to pediatricians.
"This increase in sales personnel will enable Ascent to seek additional opportunities for introducing significant new pharmaceutical products to the pediatric market," said Alan Fox, president and CEO of Ascent.
In 1997, the pediatric market for pharmaceutical products was estimated to be worth approximately $4 billion.
Currently, Ascent promotes Feverall® Acetaminophen Suppositories and Pediamist® Nasal Mist. In the second half of 1999, Ascent said it expects to begin marketing two new markets, pending FDA approval. The products are Primsol® Solution, an antibiotic for acute otitis media, and Oraped,® an improved tasting formulation of liquid prednisolone.
When Ascent first entered the market, it reported employing a sales force of 65 sales reps. PR
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
